Daewoong Pharmaceutical Q3 Operating Profit Rises 44% to 76.8 Billion Won
Revenue: 415.8 billion won; net income: 47.3 billion won
Daewoong Pharmaceutical announced on November 4 that its operating profit on a standalone basis for the third quarter of this year rose 43.5% year on year to 76.8 billion won.
An artist's rendering of Daewoong Pharmaceutical's Magok Research Institute in Gangseo-gu, Seoul. Daewoong Pharmaceutical
View original imageRevenue for the same period increased 17.1% to 415.8 billion won, while net income rose 9.9% to 47.3 billion won.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
A Daewoong Pharmaceutical official said, "The results reflect expanded exports of Nabota, a botulinum toxin product, along with growth in key businesses such as over-the-counter (OTC) medicines and digital healthcare. The increased sales share of high-margin products, led by Nabota, also contributed positively to improving overall profitability."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.